‘NRG-GY005:’ of page ‘NRG-GY005’
A Randomized Phase II/III Study of the Combination of Cediranib and Olaparib Compared to Cediranib or Olaparib Alone, or Standard of Care Chemotherapy in Women with Recurrent Platinum-Resistant or Refractory Ovarian, Fallopian Tube, or Primary Peritoneal Cancer (COCOS) Principal Investigator/Co-Principal Investigator Jung-Min Lee MD/Angeles Alvarez Secord MD, MHSc Primary Objective Phase II To asess […]
Read More